Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › AVLN

Pivotal bioVenture Partners Investment Advisor LLC position in AVLN

AVALYN PHARMACEUTICALS INC · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 866,792 shares of AVLN (AVALYN PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$24.7M, representing 10.06% of its reported portfolio and ranking #4 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)866.79K sh
Reported value held$24.69M
Portfolio Weight10.06%
First reportedQ2 2026
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's AVLN position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in AVLN in Q2 2026 at 966,792 shares (US$31.8M). Across 2 filings, Pivotal bioVenture Partners Investment Advisor LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 866,792 shares valued at US$24.7M — a reduction of -100,000 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q2 2026 966.79K $31.83M New
Q3 2026 866.79K $24.69M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AVLN and 13F data

AVLN (AVALYN PHARMACEUTICALS INC) is a Health Care company. 113 other funds we track also report a position in AVLN — the largest reported positions include Novo Holdings A/S (US$127.8M), SR ONE CAPITAL MANAGEMENT, LP (US$108.9M), PERCEPTIVE ADVISORS LLC (US$88.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AVLN

All AVLN fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held AVLN?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in AVLN?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 866.79K shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $24.69M, representing 10.06% of its reported portfolio and ranking #4.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling AVLN?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC reduced its position in AVLN.

Which other funds hold AVLN?

Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 113 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.